Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Statins: Could an old friend help the fight against COVID-19?

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • Contributors:
      UAM. Departamento de Medicina
    • بيانات النشر:
      Wiley
    • الموضوع:
      2020
    • Collection:
      Universidad Autónoma de Madrid (UAM): Biblos-e Archivo
    • نبذة مختصرة :
      This is the peer reviewed version of the following article: "Statins: Could an old friend help the fight against COVID-19?" . British Journal of Pharmacology (2020): 19 June, which has been published in final form at https://doi.org/10.1111/bph.15166. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions ; he COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has overwhelmed healthcare systems requiring the rapid development of treatments, at least, to reduce COVID-19 severity. Drug repurposing offers a fast track. Here, we discuss the potential beneficial effects of statins in COVID-19 patients based on evidence that they may target virus receptors, replication, degradation, and downstream responses in infected cells, addressing both basic research and epidemiological information. Briefly, statins could modulate virus entry, acting on the SARS-CoV-2 receptors, ACE2 and CD147, and/or lipid rafts engagement. Statins, by inducing autophagy activation, could regulate virus replication or degradation, exerting protective effects. The well-known anti-inflammatory properties of statins, by blocking several molecular mechanisms, including NF-κB and NLRP3 inflammasomes, could limit the "cytokine storm" in severe COVID-19 patients which is linked to fatal outcome. Finally, statin moderation of coagulation response activation may also contribute to improving COVID-19 outcomes ; This work and data discussed here were supported by grants from the Instituto de Salud Carlos III (ISCIII) and Fondos FEDER European Union (PI17/00119 and Red de Investigación Renal (REDINREN): RD16/0009, to M.R-O, PI17/01495 to J.E, PI18/01133 to AMR, PI19/00815 to A.O); Comunidad de Madrid (“NOVELREN” B2017/BMD3751 to M.R-O, B2017/BMD-3686 CIFRA2-CM to A.O); Spanish Ministry of Economy and Competitiveness MINECO (DTS17/00203, DTS19/00093) to J,E; “Convocatoria Dinamización Europa Investigación 2019” MINECO (EIN2019-103294 to ...
    • File Description:
      application/pdf
    • Relation:
      British Journal of Pharmacology; https://doi.org/ 10.1111/bph.15166; info:eu-repo/grantAgreement/EC/H2020/812699/EU//IMPROVE-PD; Gobierno de España. PI17/00119; Gobierno de España. RD16/0009; Gobierno de España. PI17/01495; Gobierno de España. PI18/01133; Comunidad de Madrid. B2017/BMD3751/NOVELREN; Comunidad de Madrid. B2017/BMD-3686/CIFRA2-CM; Gobierno de España. DTS17/00203; Gobierno de España. DTS19/00093; Gobierno de España. EIN2019-103294; Gobierno de España. AC18/00064; Gobierno de España. AC18/00071; Gobierno de España. DTS18/00032; British Journal of Pharmacology 177.21 (2020): 4811-5001; 0007-1188 (print); 1476-5381 (online); http://hdl.handle.net/10486/691795; 4811; 5001; 177
    • الرقم المعرف:
      10.1111/bph.15166
    • الدخول الالكتروني :
      http://hdl.handle.net/10486/691795
      https://doi.org/10.1111/bph.15166
    • Rights:
      © 2020 The British Pharmacological Society ; openAccess
    • الرقم المعرف:
      edsbas.C66B60BB